作者
Elena Kum, Matthew Patel, Nermin Diab, Mustafaa Wahab, Dena Zeraatkar, Derek K Chu, Paul M O’Byrne, Gordon H Guyatt, Imran Satia
发表日期
2023/9/11
来源
JAMA
简介
Importance
Gefapixant represents an emerging therapy for patients with refractory or unexplained chronic cough.
Objective
To evaluate the efficacy and tolerability of gefapixant for the treatment of adults with refractory or unexplained chronic cough.
Data Sources
MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science from November 2014 to July 2023.
Study Selection
Two reviewers independently screened for parallel and crossover randomized clinical trials (RCTs) that compared, in patients with refractory or unexplained chronic cough, either gefapixant with placebo, or 2 or more doses of gefapixant with or without placebo.
Data Extraction and Synthesis
Two reviewers independently extracted data. A frequentist random-effects dose-response meta-analysis or pairwise meta-analysis was used for each outcome. The GRADE (Grading of Recommendations, Assessment, Development …
学术搜索中的文章
E Kum, M Patel, N Diab, M Wahab, D Zeraatkar… - JAMA, 2023